Acta pharmaceutica Sinica. B · 2026
The polymeric nanovectors landscape for cancer immunotherapies towards advanced therapy medicinal products (ATMPs).
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Palamà Ilaria Elena, Invidia Alessandra, De Stradis Claudia, Leccese Gabriella, Baldari Clara, Cortese Barbara, Guido Clara, Giglio Andrea, Quintarelli Concetta, De Angelis Biagio, Maiorano Gabriele, Locatelli Franco, Gigli Giuseppe
Аннотация
Despite major advances in oncology, cancer remains one of the leading causes of mortality worldwide, underscoring the need for more effective and personalized therapeutic solutions. Advanced therapy medicinal products (ATMPs), including gene and cell-based therapies, have emerged as a promising frontier for immune cell engineering in oncology. However, current approaches still face several technical/safety issues, mainly associated with the delivery strategies used and their complex manufacturing processes. In this context, polymeric nanovectors (pNVs) have gained attention as a promising tool for developing efficient therapeutic delivery systems. The possibility of customizing pNVs' composition/physicochemical properties, exploiting natural/synthetic polymers, enables more precise and controlled cargo delivery to immune cells, paving the way for the development of future ATMPs-oriented strategies for cancer immunotherapy. This review highlights the recent advancements in the application of pNVs for the editing of immune cells, focusing on innovative nanotechnology-based strategies to enhance the precision and efficacy of immunotherapy with a particular emphasis on their prospective role in next-generation ATMP development.